Wegovy and Bone Density: What the Evidence Shows

Does Wegovy affect bone density — and what does the current evidence actually show?

Short answer: evidence suggests bone mineral density can fall during semaglutide treatment, but the change appears driven mainly by rapid weight loss rather than a direct effect of the drug — and most of the bone-density data comes from the lower diabetes dose, not the Wegovy obesity dose. Wegovy is semaglutide given at 2.4 mg once weekly for weight management. That dose distinction runs through this whole article, because the trials that actually measured bone density mostly used semaglutide at 1.0 mg, the diabetes dose.

A 2025 review in Osteoporosis International set out how weight-loss medications interact with the skeleton, concluding that the bone changes broadly resemble those caused by any significant calorie restriction rather than a toxic effect on bone Karam et al., Osteoporosis International, 2025.

Why does any significant weight loss tend to reduce bone mineral density?

Because bone is living tissue that adapts to the load placed on it. When the body loses a large amount of weight quickly — through dieting, surgery or medication — bone and muscle are lost alongside fat. A 2025 Bone Research review catalogued the mechanisms: reduced mechanical loading on a lighter frame, expansion of fat within the bone marrow, hormonal disruption (oestrogen, parathyroid hormone, IGF-1), nutritional shortfalls, and metabolic and gut-hormone changes Liu et al., Bone Research, 2025.

That same review noted that calcium and vitamin D supplementation, while helpful, cannot completely prevent weight-loss-related bone loss on their own. This matters because it reframes the question: the issue is less "is the drug toxic to bone?" and more "how do we protect the skeleton during rapid weight loss?"

What did clinical trials of semaglutide find — and which dose were they testing?

The most informative bone-density trial tested semaglutide at 1.0 mg — the diabetes dose — not the 2.4 mg Wegovy dose. In a 2024 phase 2 trial published in EClinicalMedicine, 64 adults at increased fracture risk (mostly postmenopausal women, mean age 63) received once-weekly semaglutide 1.0 mg or placebo. The semaglutide group had lower total hip bone density (an estimated treatment difference of -0.020 g/cm², p=0.001) and lower lumbar spine bone density (-0.018 g/cm², p=0.007), with a higher marker of bone breakdown (CTX). The investigators attributed these changes to the accompanying weight loss — about 6.8 kg more than placebo Hansen et al., EClinicalMedicine, 2024.

The shift towards bone resorption is consistent with that picture: a 2025 Bone Research review noted semaglutide raised the bone-breakdown marker CTX by 54.8% in this context Liu et al., Bone Research, 2025. We are not aware of a large randomised trial reporting bone mineral density at the Wegovy 2.4 mg obesity dose — so for the obesity dose specifically, the strongest evidence is about fractures rather than BMD.

Does Wegovy raise your risk of fractures? What the FDA label and SELECT data say

This is where the obesity-dose (2.4 mg) evidence lives. In the large SELECT cardiovascular outcomes trial of semaglutide 2.4 mg, female hip and pelvic fractures occurred in 1.0% (24 of 2,448) of the semaglutide group versus 0.2% (5 of 2,424) of placebo, and the gap was wider among women aged 75 and over — 2.4% (17 of 703) versus 0.6% (4 of 663) Karam et al., Osteoporosis International, 2025.

For contrast, a 2025 real-world cohort of 1,845 people with type 2 diabetes found GLP-1 use associated with a roughly 31% lower risk of osteoporosis (adjusted hazard ratio 0.69) — but this was a diabetes population using a mix of GLP-1 medicines, not the Wegovy obesity dose Chen et al., Frontiers in Endocrinology, 2025.

Who is most at risk of bone loss while taking Wegovy?

The groups that show up most clearly in the data are older adults and postmenopausal women. The phase 2 BMD trial was deliberately run in adults at increased fracture risk, mostly postmenopausal women with a mean age of 63 Hansen et al., EClinicalMedicine, 2024. In SELECT, the fracture signal was concentrated in women — and strongest in those aged 75 and over Karam et al., Osteoporosis International, 2025.

A 2025 pilot study in older adults (mean age 72.7) with prediabetes or type 2 diabetes found no statistically significant change in whole-body bone density over 20 weeks of semaglutide 1.0 mg, but a non-significant trend toward bone loss versus lifestyle counselling, alongside greater weight loss Dinkla et al., Frontiers in Aging, 2025. The practical read: if you are postmenopausal, over 40, or already have low bone density, you have more reason to know your baseline.

Can exercise or diet protect your bones when you are on Wegovy?

The most encouraging finding in this whole field is that exercise appears to protect bone during GLP-1 weight loss. In a 2024 JAMA Network Open secondary analysis, 195 adults with obesity were split into exercise alone, drug alone, or both. The drug alone reduced hip bone density, while combining it with exercise preserved bone despite the largest weight loss of any group. Importantly, this trial used liraglutide 3.0 mg, a related GLP-1 medication — not semaglutide or Wegovy — so it points the direction rather than proving it for Wegovy specifically Jensen et al., JAMA Network Open, 2024.

In practice, the protective steps are consistent across the evidence:

• Resistance training (weights, bands, bodyweight) 2–3 times a week to load muscle and bone.
• Weight-bearing activity — walking, stairs, dancing.
• Adequate protein to defend lean mass during weight loss.
• Calcium and vitamin D sufficiency — useful, though not a complete safeguard on their own.

Should you have a bone density check before — and during — Wegovy treatment?

If you are postmenopausal, over 40, or already have low bone density, a baseline scan before or early in treatment is a sensible precaution — because there is currently no routine NHS bone-monitoring programme for people on weight-loss injections. Without a baseline, gradual bone change goes unmeasured until a problem appears.

Why a radiation-free REMS scan suits repeat monitoring

Standard DEXA scans use a small dose of X-ray radiation, which makes frequent re-scanning less appealing. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely across a one- or two-year course of treatment — exactly what monitoring on a weight-loss injection calls for. You can book a screening or read about our bone health assessment and where we screen across the UK.

What does NICE guidance say about bone monitoring for people taking Wegovy in the UK?

NICE recommends semaglutide (Wegovy) for managing overweight and obesity for a maximum of two years within a specialist weight management service, for people meeting specific BMI and referral criteria — but the guidance does not include any bone density monitoring NICE TA875, 2023. That absence is a matter of fact.

Whether it is a gap is a judgement. Screen My Bones considers it one, given the emerging bone-density and fracture data above — but that is our view, not a NICE position. If you are starting or already on Wegovy, knowing your bone status puts you in control of a question the standard pathway does not currently ask.

---

This article is part of our weight-loss medications and bone health series. For a wider look at GLP-1 medicines and the skeleton, see do Ozempic and weight-loss injections cause bone loss?